Neem Biotech, a South Wales based R&D pharmaceutical biotech working in the field of novel antimicrobial drug development, and the Welsh Wound Innovation Centre recently attended the Royal College of Physicians’ Innovation in Medicine Conference 2018 where Neem presented their data around wound-relevant biofilms.
The promising laboratory data presented reinforces the role of quorum sensing inhibition in virulence factor regulation and biofilm disruption, with implications for management of antimicrobial resistance.
Dr Graham Dixon, Neem’s CEO and Prof Keith Harding, Medical Director of the Welsh Wound Innovation Centre, teamed up after the event to share their thoughts about the management of infection in hard-to-heal wounds.
Wound infection is an area that presents much opportunity for clinical innovations that will benefit both people with wounds and healthcare providers. Neem Biotech is pleased to be playing a pioneering role in this field”.
Graham Dixon, Chief Executive Officer, Neem Biotech
Prof Keith Harding, Medical Director at the Welsh Wound Innovation Centre, said: “Wounds and problems associated with wound healing, including infection management, are an important clinical issue. The Welsh Wound Innovation Centre is pleased to be working with Neem in the development of their innovative approach to managing infection in hard-to-heal wounds to make sure that the right treatment is delivered to the right patient at the right time”.